Wilmington, DE, United States of America

Lixin Shao

USPTO Granted Patents = 32 

 

 

Average Co-Inventor Count = 6.3

ph-index = 11

Forward Citations = 481(Granted Patents)


Location History:

  • Newark, DE (US) (2014 - 2016)
  • Newark, DE (2016)
  • Wilmington, DE (US) (2017 - 2024)

Company Filing History:


Years Active: 2014-2025

Loading Chart...
Loading Chart...
Loading Chart...
32 patents (USPTO):Explore Patents

Title: Lixin Shao: A Pioneering Innovator in Pharmaceutical Development

Introduction

Lixin Shao is a distinguished inventor based in Wilmington, Delaware, with an impressive portfolio of 30 patents. His groundbreaking work primarily focuses on the development of compounds that serve as inhibitors for critical biochemical pathways, particularly in the context of treating complex diseases.

Latest Patents

Among his latest patents are "Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors" and "Heterocyclic derivatives as PI3K inhibitors". These patents relate to innovative compounds that can be used to inhibit PI3K-γ, offering potential therapeutic applications for various disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

Career Highlights

Lixin Shao has made significant strides in the pharmaceutical sector through his work with notable companies, including Incyte Corporation and Incyte Holdings Corporation. His expertise and contributions have considerably advanced drug development processes in combating serious diseases.

Collaborations

Throughout his career, Lixin has collaborated with numerous professionals, including his coworkers Stacey Shepard and Nikoo Falahatpisheh. Their combined expertise has played a crucial role in achieving the innovative outcomes for which Lixin is recognized.

Conclusion

Lixin Shao's contributions to the field of pharmaceuticals highlight his dedication to innovation and improving human health. With a solid patent portfolio and ongoing research, he continues to be a valuable asset in the quest for new therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…